Dementia

Alzheimer Society of Canada. Prevalence and monetary costs of dementia in Canada. Available: www.alzheimer.ca/~/media/Files/national/Statistics/PrevalenceandCostsofDementia_EN.pdf (accessed Sep. 19, 2016).

Chang F Patel T Schulz ME . The “rising tide” of dementia in Canada: what does it mean for pharmacists and the people they care for? Can Pharm J (Ott) 2015;148(4):193-9.

Chertkow H Feldman HH Jacova C . Definitions of dementia and predementia states in Alzheimer’s disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia. Alzheimers Res Ther 2013;5(suppl 1):S2.

Sheehan B . Assessment scales in dementia. Ther Adv Neurol Disord 2012;5(6):349-58.

Hildreth KL Church S . Evaluation and management of the elderly patient presenting with cognitive complaints. Med Clin North Am 2015;99(2):311-35.

Alzheimer Society of Canada. Mild cognitive impairment. Available: www.alzheimer.ca/~/media/Files/national/Other-dementias/other_dementias_MCI_e.pdf (accessed Sep. 19, 2016).

Bruscoli M Lovestone S . Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr 2004;16(2):129-40.

Matthews FE Stephan BCM McKeith IG . Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? J Am Geriatr Soc 2008;56(8):1424-33.

Palmer K Bäckman L Winblad B . Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease. Am J Geriatr Psychiatry 2008;16(7):603-11.

Ganguli M Snitz BE Saxton JA . Outcomes of mild cognitive impairment by definition: a population study. Arch Neurol 2011;68(6):761-7.

Jack CR Shiung MM Gunter JL . Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology 2004;62(4):591-600.

Schmidtke K Hermeneit S . High rate of conversion to Alzheimer’s disease in a cohort of amnestic MCI patients. Int Psychogeriatr 2008;20(1):96-108.

Artero S Ancelin M-L Portet F . Risk profiles for mild cognitive impairment and progression to dementia are gender specific. J Neurol Neurosurg Psychiatry 2008;79(9):979-84.

Mitchell AJ Shiri-Feshki M . Rate of progression of mild cognitive impairment to dementia—meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand 2009;119(4):252-65.

Larrieu S Letenneur L Orgogozo JM . Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology 2002;59(10):1594-99.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington (VA): American Psychiatric Publishing; 2013.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington (DC): American Psychiatric Publishing; 2000.

Muangpaisan W . Clinical differences among four common dementia syndromes. Geriatr Aging 2007;10(425):9.

Reitz C . Genetic diagnosis and prognosis of Alzheimer’s disease: challenges and opportunities. Expert Rev Mol Diagn 2015;15(3):339-48.

Alzheimer Society of Canada. Vascular dementia. Available: www.alzheimer.ca/en/About-dementia/Dementias/Vascular-Dementia (accessed Sep. 19, 2016).

Alzheimer Society of Canada. Lewy body dementia. Available: www.alzheimer.ca/en/About-dementia/Dementias/Lewy-Body-Dementia (accessed Sep. 19, 2016).

Zupancic M Mahajan A Handa K . Dementia with Lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord 2011;13(5).

Alzheimer Society of Canada. Frontotemporal dementia. Available: www.alzheimer.ca/en/About-dementia/Dementias/Frontotemporal-Dementia-and-Pick-s-disease (accessed Sep. 19, 2016).

Feldman HH Jacova C Robillard A . Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ 2008;178(7):825-36.

Shastri A Bangar S Holmes J . Obstructive sleep apnoea and dementia: is there a link? Int J Geriatr Psychiatry 2016;31(4):400-5.

Poggesi A Inzitari D Pantoni L . Atrial fibrillation and cognition: epidemiological data and possible mechanisms. Stroke 2015;46(11):3316-21.

de Bruijn RF Heeringa J Wolters FJ . Association between atrial fibrillation and dementia in the general population. JAMA Neurol 2015;72(11):1288-94.

Folstein MF Folstein SE McHugh PR . “Mini-Mental State.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189-98.

Nasreddine ZS Phillips NA Bédirian V . The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53(4):695-9.

Sunderland T Hill JL Mellow AM . Clock drawing in Alzheimer’s disease. A novel measure of dementia severity. J Am Geriatr Soc 1989;37(8):725-9.

Iracleous P Nie JX Tracy CS . Primary care physicians’ attitudes towards cognitive screening: findings from a national postal survey. Int J Geriatr Psychiatry 2010;25(1):23-9.

Ismail Z Mulsant BH Herrmann N . Canadian academy of geriatric psychiatry survey of brief cognitive screening instruments. Can Geriatr J 2013;16(2):54-60.

Ostrosky-Solís F López-Arango G Ardila A . Sensitivity and specificity of the Mini-Mental State Examination in a Spanish-speaking population. Appl Neuropsychol 2000;7(1):25-31.

Hodkinson HM . Evaluation of a mental test score for assessment of mental impairment in the elderly. Age Ageing 1972;1(4):233-8.

Jitapunkul S Pillay I Ebrahim S . The abbreviated mental test: its use and validity. Age Ageing 1991;20(5):332-6.

Borson S Scanlan J Brush M . The Mini-Cog: a cognitive “vital signs” measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry 2000;15(11):1021-7.

Brodaty H Moore CM . The Clock Drawing Test for dementia of the Alzheimer’s type: a comparison of three scoring methods in a memory disorders clinic. Int J Geriatr Psychiatry 1997;12(6):619-27.

Brodaty H Pond D Kemp NM . The GPCOG: a new screening test for dementia designed for general practice. J Am Geriatr Soc 2002;50(3):530-4.

Solomon PR Hirschoff A Kelly B . A 7 minute neurocognitive screening battery highly sensitive to Alzheimer’s disease. Arch Neurol 1998;55(3):349-55.

Buschke H Kuslansky G Katz M . Screening for dementia with the memory impairment screen. Neurology 1999;52(2):231-8.

Daneschvar HL Aronson MD Smetana GW . Do statins prevent Alzheimer’s disease? A narrative review. Eur J Intern Med 2015;26(9):666-9.

Thomas J Thomas CJ Radcliffe J . Omega-3 fatty acids in early prevention of inflammatory neurodegenerative disease: a focus on Alzheimer’s disease. Biomed Res Int 2015;2015:172801.

Vellas B Coley N Ousset P-J . Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012;11(10):851-9.

DeKosky ST Williamson JD Fitzpatrick AL . Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008;300(19):2253-62.

Andrieu S Coley N Lovestone S . Prevention of sporadic Alzheimer’s disease: lessons learned from clinical trials and future directions. Lancet Neurol 2015;14(9):926-44.

Hogan DB Bailey P Black S . Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ 2008;179(10):1019-26.

Heyn P Abreu BC Ottenbacher KJ . The effects of exercise training on elderly persons with cognitive impairment and dementia: a meta-analysis. Arch Phys Med Rehabil 2004;85(10):1694-704.

Forbes D Forbes SC Blake CM . Exercise programs for people with dementia. Cochrane Database Syst Rev 2015;(4):CD006489.

Fiatarone Singh MA Gates N Saigal N . The Study of Mental and Resistance Training (SMART) study—resistance training and/or cognitive training in mild cognitive impairment: a randomized, double-blind, double-sham controlled trial. J Am Med Dir Assoc 2014;15(12):873-80.

Harry RDJ Zakzanis KK . A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer’s disease: a meta-analysis. Hum Psychopharmacol 2005;20(3):183-7.

Birks J . Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006;(1):CD005593.

Wilcock G Howe I Coles H . A long-term comparison of galantamine and donepezil in the treatment of Alzheimer’s disease. Drugs Aging 2003;20(10):777-89.

Winblad B Cummings J Andreasen N . A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease—rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007;22(5):456-67.

Gauthier S Emre M Farlow MR . Strategies for continued successful treatment of Alzheimer’s disease: switching cholinesterase inhibitors. Curr Med Res Opin 2003;19(8):707-14.

Cagnin A Cester A Costa B . Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer’s disease. Neurol Sci 2015;36(3):457-63.

Han HJ Lee JJ Park SA . Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer’s disease. J Clin Neurol 2011;7(3):137-42.

Sadowsky C Perez JA Bouchard RW . Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch. CNS Neurosci Ther 2010;16(1):51-60.

Sink KM Thomas J Xu H . Dual use of bladder anticholinergics and cholinesterase inhibitors: long-term functional and cognitive outcomes. J Am Geriatr Soc 2008;56(5):847-53.

Reisberg B Doody R Stöffler A . Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003;348(14):1333-41.

McShane R Areosa Sastre A Minakaran N . Memantine for dementia. Cochrane Database Syst Rev 2006;(2):CD003154.

Schmidt R Hofer E Bouwman FH . EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer’s disease. Eur J Neurol 2015;22(6):889-98.

Lin JS O’Connor E Rossom R . Screening for cognitive impairment in older adults: an evidence update for the U.S. Preventive Services Task Force. Rockville (MD): Agency for Healthcare Research and Quality; 2013. Report No.: 14-05198-EF-1.

Rountree SD Chan W Pavlik VN . Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 2009;1(2):7.

Rountree SD Atri A Lopez OL . Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimers Dement 2013;9(3):338-45.

Hogan DB . Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease. Can J Psychiatry 2014;59(12):618-23.

McGuinness B Craig D Bullock R . Statins for the treatment of dementia. Cochrane Database Syst Rev 2014;(7):CD007514.

Stella F Radanovic M Canineu PR . Anti-dementia medications: current prescriptions in clinical practice and new agents in progress. Ther Adv Drug Saf 2015;6(4):151-65.

Doody RS Thomas RG Farlow M . Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370(4):311-21.

Siemers ER Sundell KL Carlson C . Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement 2016;12(2):110-20.